- Home
- SPRY vs BCSF Comparison
SPRY vs BCSF Comparison
Compare SPRY & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPRY | BCSF |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 818.0M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SPRY | BCSF |
|---|---|---|
| Price | $9.19 | $13.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $35.00 | $15.00 |
| AVG Volume (30 Days) | ★ 1.1M | 536.1K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | ★ 14.03% |
| EPS Growth | ★ 114.04 | N/A |
| EPS | N/A | ★ 1.10 |
| Revenue | ★ $89,149,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $119.97 | N/A |
| P/E Ratio | ★ N/A | $11.66 |
| Revenue Growth | ★ 297063.34 | N/A |
| 52 Week Low | $6.66 | $12.49 |
| 52 Week High | $18.63 | $19.21 |
Technical Indicators
Market Signals| Indicator | SPRY | BCSF |
|---|---|---|
| Relative Strength Index (RSI) | 42.29 | 45.41 |
| Support Level | $8.61 | $12.49 |
| Resistance Level | $10.44 | $14.53 |
| Average True Range (ATR) | 0.50 | 0.43 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 35.48 | 44.36 |
Price Performance
Historical ComparisonAbout SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.